These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11374839)

  • 1. Strong association between P53 protein accumulation, serum antibodies and gene mutation in non-small cell lung cancer.
    Niklinska W; Burzykowski T; Laudanski J; Chyczewska E; Chyczewski L; Niklinski J
    Folia Histochem Cytobiol; 2001; 39(2):51-6. PubMed ID: 11374839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
    Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
    Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exon 8 mutation of p53 gene associated with nodal metastasis in non-small-cell lung cancer.
    Lee LN; Shew JY; Sheu JC; Lee YC; Lee WC; Fang MT; Chang HF; Yu CJ; Yang PC; Luh KT
    Am J Respir Crit Care Med; 1994 Dec; 150(6 Pt 1):1667-71. PubMed ID: 7952630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
    Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
    Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer.
    Laudanski J; Burzykowski T; Niklinska W; Chyczewski K; Furman M; Niklinski J
    Lung Cancer; 1998 Dec; 22(3):191-200. PubMed ID: 10048472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 gene mutation and protein expression in operable non-small cell lung cancer in Poland.
    Niklinska W; Burzykowski T; Chyczewski L; Rusin MR; Furman M; Laudanski J; Chyczewska E; Sulik M; Niklinski J
    Eur J Cancer Prev; 2000 Apr; 9(2):81-7. PubMed ID: 10830574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.
    Tomizawa Y; Kohno T; Fujita T; Kiyama M; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Nakajima T; Yokota J
    Oncogene; 1999 Jan; 18(4):1007-14. PubMed ID: 10023676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
    Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
    Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular mechanisms of lung cancer development at its different stages in nuclear industry workers].
    Rusinova GG; Vyazovskaya NS; Azizova TV; Revina VS; Glazkova IV; Generozov EV; Zakharzhevskaya NB; Guryanov MY; Belosokhov MV; Osovets SV
    Arkh Patol; 2015; 77(2):10-15. PubMed ID: 26027393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer.
    Wu HH; Chu YC; Wang L; Tsai LH; Lee MC; Chen CY; Shieh SH; Cheng YW; Lee H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S336-47. PubMed ID: 22688662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
    Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
    BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
    Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
    Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
    Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
    Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum anti-P53 antibodies (AB-anti-P53) in patients with advanced non-small cell lung cancer (NSCLC)].
    Skrzypski M; Szymanowska A; Janowicz A; Dziadziuszko R; Ramlau R; Kozielski J; Pilarska-Machowicz A; Dobrzańska Z; Bigda J; Krzakowski M; Jassem E; Jassem J
    Pneumonol Alergol Pol; 2002; 70(7-8):353-8. PubMed ID: 12708076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer.
    Laudanski J; Niklinska W; Burzykowski T; Chyczewski L; Niklinski J
    Eur Respir J; 2001 Apr; 17(4):660-6. PubMed ID: 11401061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
    Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of serum p53 antibodies in lung cancer.
    Mattioni M; Soddu S; Prodosmo A; Visca P; Conti S; Alessandrini G; Facciolo F; Strigari L
    BMC Cancer; 2015 Mar; 15():148. PubMed ID: 25884692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.